HS
SPRY icon

HighVista Strategies’s ARS Pharmaceuticals SPRY Stock Holding History

HighVista Strategies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,434
Closed -$149K – 98
2021
Q4 		$149K Hold
22,434
– – 0.12% 69
2021
Q3 		$224K Sell
22,434
-3,472
-13% -$85.6K 0.15% 72
2021
Q2 		$800K Buy
25,906
+11,839
+84% +$380K 0.57% 48
2021
Q1 		$614K Buy
+14,067
New +$666K 0.46% 56

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighVista Strategies's SPRY Position: Q1 2022 in Review

HighVista Strategies sold out of ARS Pharmaceuticals (SPRY) in Q1 2022, closing a stake of 22,434 shares — an estimated $149K sold.

HighVista Strategies first reported a position in SPRY in Q1 2021 and held it in 4 quarters. The position peaked at $800K in Q2 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

  • HighVista Strategies reported no remaining ARS Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • HighVista Strategies sold 22,434 ARS Pharmaceuticals shares in Q1 2022, an estimated $149K.
  • HighVista Strategies first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • HighVista Strategies's ARS Pharmaceuticals position peaked at $800K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.